Growth Hormone in the Treatment of HIV-Associated Wasting
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00489528|
Recruitment Status : Completed
First Posted : June 21, 2007
Last Update Posted : October 22, 2013
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections HIV Wasting Syndrome||Drug: Somatropin; Recombinant human growth hormone (r hGH)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Recombinant Human Growth Hormone (Serostim) in the Treatment of HIV-Associated Catabolism/Wasting|
|Study Start Date :||July 1997|
|Actual Study Completion Date :||March 2002|
- To confirm the clinical efficacy of Serostim compared with placebo, based on an endpoint of exercise function change.
- To establish an optimal dose of Serostim, based on the endpoint of lean body mass (LBM) change.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00489528
|Study Director:||Elizabeth Svanbert, MD, PhD|